View Older Stories View More Recent Stories
-
Near-Term Volatility Expected on Exec Shift, But Fundamentals Inact for Synta Pharma (SNTA) - Roth
-
BioLineRx (BLRX) Prices 8.4M Offering at $2.50/ADS
-
OvaScience (OVAS) Prices 5M Offering at $10/Share
-
Investors Probably Already Looking Past SolarCity (SCTY) Accounting Snafu - Roth
-
Roth Capital Starts Constant Contact (CTCT) at Buy
-
Quadrant 4 Systems to Present at Roth Capital Partners 26th Annual Conference
-
BioLineRx (BLRX) Lower on Stock Offering
-
RGS Energy to Present at the 26th Annual ROTH Conference on March 10, 2014
-
Dendreon (DNDN) Makes Progress in FY13, But Road Ahead Still Bumpy - Roth
-
Roth Still Positive on Ligand (LGND) Following Promacta sNDA Submission
-
Pedevco (PED) to Offer Common Stock
-
Neptune Technologies (NEPT) Prices 10M Shares at $2.50
-
Broadwind Energy to Present at the 26th Annual Roth Conference
-
Neptune Tech (NEPT) Commences Common Stock Offering
-
Landec to Present at the 26th Annual ROTH Conference on March 12, 2014
-
I.D. Systems to Present at 26th Annual ROTH Conference on March 11, 2014
-
Black Diamond to Present at the 26th Annual ROTH Conference on March 11, 2014
-
Speed Commerce to Present at the 26th Annual ROTH Conference on March 11, 2014
-
SolarCity (SCTY) Q1 Outlook Constrained, But FY14 Deployment Outlook Kept in Check - Roth
-
Edgewater to Present at the 26th Annual ROTH Conference on March 12, 2014
-
Pharmacyclics' (PCYC) IMBRUVICA Drives Strong Q4 Results; Roth Boosts PT to $183
-
Pharmacyclics (PCYC) PT Raised to $183 at Roth Capital
-
Roth Reaffirms Curis (CRIS) at Buy; Erivedge, Internal Pipeline Both Ongoing Strengths
-
Several Themes in Focus for SolarCity's (SCTY) Q4 Report; Upside Surprises Unlikely - Roth
-
ZAGG Inc to Present at 26th Annual Roth Conference
-
Roth Capital Downgrades Hecla Mining (HL) to Neutral
-
Curis Reports Fourth Quarter and Year-End 2013 Financial Results
-
Roth Eases Estimates on Enphase (ENPH) Following Q4 Results; Maintains 'Buy' Rating
-
Roth Capital Downgrades Silvercrest Mines (SVLC) to Neutral
-
Roth Lifts PT on Retrophin (RTRX) to $51; Impressive Manchester Pharma Purchase Will Bolster Business Plan
-
Concert Pharmaceuticals (CNCE) IPO Jumps Higher
-
Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded
-
Roth Capital Boosts PT on Pharmacyclics (PCYC) to $166; Strong IMBRUVICA Sales Ramp Expected
-
Roth Capital Downgrades DepoMed Inc (DEPO) to Neutral
-
Roth Capital Upgrades Nanosphere (NSPH) to Buy
-
MacroGenics Announces Pricing of Public Offering of Common Stock
-
Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in Focus
-
Notable Analyst Rating Changes 02/12: (CROX) (S) (ZTS) Upgraded; (AMZN) (DF) (GMCR) Downgraded
-
Pre-Open Stock Movers 2/12: (OC) (CSTE) (TRIP) Higher; (VTUS) (RLOC) (PRGN) Lower (more...)
-
Roth Capital Starts Rally Software Development (RALY) at Buy
-
Roth Capital Starts Orion Energy Systems (OESX) at Buy
-
Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts Ahead
-
Canadian Solar (CSIQ) Prices 2.78M Common, $130M Convertible Notes Offering
-
Roth Capital Downgrades Insperity (NSP) to Neutral
-
MacroGenics Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 02/07: (PG) (ANGI) (SODA) (PTEN)
-
SodaStream (SODA)/ Pepsi (PEP) Deal is Unlikely, Says Roth Capital
-
Pyramid Oil (PDO) and Yuma Enter Merger Pact
-
Roth Capital Reaffirms Spectrum (SPPI) at Buy; FDA Grants Beleodaq NDA Priority Review
-
Top Image Systems, Ltd. Closes $15.0 Million Public Offering of Ordinary Shares Including Exercise in Full of Overallotment Option

